Revenue Recognition and Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2020

Revenue Recognition and Collaborative Arrangements

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2020		2019		2020		2019
Royalties from a related party - RELVAR/BREO	$	45,570	$	47,086	$	101,719	$	89,826
Royalties from a related party - ANORO		11,199		10,635		21,049		19,205
Royalties from a related party - TRELEGY		15,633		9,842		31,768		17,171
Total royalties from a related party		72,402		67,563		154,536		126,202
Less: amortization of capitalized fees paid to a related party		(3,456)		(3,456)		(6,912)		(6,912)
Royalty revenue		68,946		64,107		147,624		119,290
Strategic alliance - MABA program		10,000		—		10,000		—
Total net revenue from GSK	$	78,946	$	64,107	$	157,624	$	119,290